AI Article Synopsis
- The study evaluated the effectiveness, safety, and tolerance of a combination medication (Mioreol) containing donepezil and memantine for Alzheimer's disease patients.
- 497 patients, averaging 75.4 years old and suffering from moderate to severe dementia, were treated for 3 months, with their cognitive and emotional functions measured using various assessments.
- Results showed significant cognitive and emotional improvements, confirming Mioreol's efficacy and safety for this patient population.
Article Abstract
Objective: The aim of the study was to evaluate the clinical efficacy, safety, and tolerability of a fixed-dose combination of donepezil and memantine (Mioreol) in patients with Alzheimer's disease (AD) and AD with cerebrovascular pathology.
Material And Methods: 497 patients with moderate to severe dementia, average age 75.4+6.81 years, received Mioreol (donepezil 10 mg+memantine 20 mg). Treatment efficacy was assessed using the MMSE, clock drawing, Sandoz Clinical Geriatric Scale, and Clinical Global Impressions after 3 months of therapy. All adverse events during treatment were recorded.
Results: The transition to Mioreol was accompanied by a reliable improvement in cognitive functions, emotional-behavioral indicators and neuropsychiatric status in general.
Conclusions: Mioreol demonstrated clinical efficacy, safety and good tolerability in patients with AD and AD with cerebrovascular pathology with moderate to severe dementia syndrome.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.17116/jnevro202412409134 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!